C9073 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Short descriptor: Brexucabtagene autoleucel ca
Look up C9073 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
C9073 is the HCPCS Level II code for Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (2026). It belongs to Section C — Outpatient PPS (Hospital). Under Medicare, its coverage status is: Special coverage instructions apply. Part B pricing methodology: Statute.
Classification & CMS Attributes
- Section
- C: Outpatient PPS (Hospital)
- Medicare Coverage
- Special coverage instructions apply (code D)
- Part B Pricing
- Statute (indicator 53)
- Type of Service
- Other medical items or services
- Effective Date
- 2021-04-01
- Termination Date
- 2021-03-31
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference C9073 with the canonical source and edition:
C9073 — Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/C9073
Canonical URL: https://icd10codingpro.com/hcpcs-codes/C9073